Accessibility Menu
Century Therapeutics logo

Century Therapeutics(NASDAQ) IPSC

Market Cap$357.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 Year-94%
1 Year+290%
1 Month-12%
$1.98
-1.00%
-0.02Today
After hours$1.99+$0.01 (+0.25%)
Century Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.982026-08-10
Century Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.982026-08-03
1 month-12%USD 2.252026-07-10
3 month-13.54%USD 2.292026-05-12
Year to date+99.03%USD 0.992025-12-31
1 year+290.3%USD 0.512025-08-08
3 year-29.29%USD 2.802023-08-11
5 year-93.63%USD 31.102021-08-11
Since inception-91.33%USD 22.832021-06-18

Century Therapeutics Financials at a Glance

Market Cap

$357.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$107.78M

EPS (TTM)

-$1.11

P/E Ratio

-1.79

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$1.98

Volume

21

Open

$1.99

Previous Close

$1.98

Daily Range

$1.96 - $2.02

52-Week Range

$0.44 - $3.04

Estimated Earnings Date

Aug 13, 2026

IPSC News

Foolcom-Featured.png

Century Reports Flat Loss in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025

IPSC: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Century Therapeutics

Century Therapeutics develops cell therapies for cancer and autoimmune diseases. Its treatments aim to help patients with few other options. The company uses lab-grown immune cells to target disease more precisely.

Cell Therapy Lineup: What’s on the Table?

  • CNTY-101: Lab-grown immune cell therapy for B-cell lymphoma and autoimmune diseases. (100% of revenue in Q2 2025)
  • CNTY-103: Immune cell therapy targeting brain cancer called glioblastoma.
  • CNTY-102: Dual-targeted therapy for B-cell cancers, using engineered T cells.
  • CNTY-104: Multi-target therapy for acute myeloid leukemia, a blood cancer.
  • CNTY-106: Therapy for multiple myeloma, a cancer of plasma cells.

Growth Moves: Century’s Expansion Playbook

  • Acquired Clade Therapeutics in April 2024, adding new T cell programs.
  • Formed key technology partnership with FUJIFILM Cellular Dynamics for stem cell access.
  • Ended collaboration with Bristol-Myers Squibb in March 2025, shifting focus to internal pipeline.
  • Reduced workforce by 51% in July 2025 to streamline operations and cut costs.

Why Century’s Approach Stands Out

Century uses stem cells to create “off-the-shelf” immune therapies, aiming for broad patient access. Its gene-editing and Allo-Evasion technology help reduce immune rejection. In-house manufacturing supports cost control and supply reliability.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Operating loss was $35 million in Q2 2025, up 0.3% year-on-year.
  • Cash and investments totaled $158.6 million as of June 30, 2025.
  • Net cash used in operations was $62.2 million for the first half of 2025.
  • Market cap was $48.66 million as of June 30, 2025.

Bottom Line

Century has shifted from partnerships to focus on its own cell therapy pipeline. The company is adapting through restructuring and targeted investment in core programs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

78

CEO

Brent Pfeiffenberger, PharmD

Website

www.centurytx.com

Headquarters

Philadelphia, PA 19104, US

IPSC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-53.23%

Return on Capital

-7.43%

Return on Assets

-33.01%

Earnings Yield

-55.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$357.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

180.35M

Volume

21

Avg. Volume

1.25M

Financials (TTM)

Gross Profit

-$52.39M

Operating Income

-$116.94M

EBITDA

-$89.90M

Operating Cash Flow

-$94.50M

Capital Expenditure

-$1.41M

Free Cash Flow

-$95.91M

Cash & ST Invst.

$134.80M

Total Debt

$48.03M

Century Therapeutics Performance Analysis

Century Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,199,000N/A
20232023-12-31USD 2,235,000-57.0%
20242024-12-31USD 6,589,000194.8%
20252025-12-31USD 109,164,0001556.8%
Century Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Century Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2730.1%
20232023-12-31USD -2.301.6%
20242024-12-31USD -1.61-30.2%
20252025-12-31USD -0.11-93.1%
Century Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-142.7%
Q32025-09-30-5.3%
Q42025-12-3145.0%
Q12026-03-31-13.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$3.00M

-102.8%

Gross Margin

0.00%

N/A

Market Cap

$357.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.58M

N/A

Employees

78

N/A

Net Income

-$21.65M

-128.3%

EBITDA

-$18.64M

-123.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$134.80M

-18.4%

Total Debt

$48.03M

-8.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$43.94M

-8.1%

Short Term Debt

$4.08M

-16.4%

Return on Assets

-33.01%

N/A

Return on Invested Capital

-37.36%

N/A

Free Cash Flow

-$25.83M

+26.4%

Operating Cash Flow

-$25.24M

+27.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLKOutlook Therapeutics, Inc.
$1.15+12.75%
EQEquillium, Inc.
$2.19+3.79%
CUECue Biopharma, Inc.
$26.10-3.76%
KPTIKaryopharm Therapeutics Inc.
$1.96-7.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.52-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.80-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.73+0.01%
SPCXSpace Exploration Technologies
$138.74+0.04%

Questions About IPSC

What is the current price of Century Therapeutics?

Century Therapeutics is trading at $1.98 per share.

What is the 52-week range for Century Therapeutics?

Over the past 52 weeks, Century Therapeutics has traded between $0.44 and $3.04.

How much debt does Century Therapeutics have?

As of the most recent reporting period, Century Therapeutics reported total debt of $48.03M.

How much cash does Century Therapeutics have on hand?

Century Therapeutics reported $51.40M in cash and cash equivalents in its most recent financial results.

What is Century Therapeutics’s dividend yield?

Century Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services